PPARγ agonists (Pioglitazone, rosilglitazone) showed some benefit with their antifibrotic properties but didn’t gain widespread use because of their side effects like risk of bladder cancer, cardiac events and weight gain5. The gene discussed is PPARG; the disease is urinary bladder cancer.